共 50 条
- [41] A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Loges, SonjaGjertsen, Bjorn TorreHeuser, MichaelBen-Batalla, I.Micklem, DavidJorg, ChromikKebenko, MaximFiedler, Walter M.Cortes, Jorge E.
- [42] A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)[J]. HAEMATOLOGICA, 2019, 104 (04) : E131 - E133Ades, LionelGuerci-Bresler, AgnesCony-Makhoul, PascaleLegros, LaurenceSebert, MarieBraun, ThorstenDelaunay, JacquesDesseaux, KristellChevret, SylvieFenaux, Pierre
- [43] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1579 - 1587Zhang, YiZhang, QikeLiu, QingchiDang, HuibingGao, SujunWang, WeiZhou, HuChen, YuqingMa, LiangmingWang, JishiYang, HaipingLu, BinhuaYin, HewenWu, LiqingSuo, ShanshanZhao, QingweiTong, HongyanJin, Jie
- [44] Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study[J]. BLOOD, 2015, 126 (23)Chari, AjaiChhabra, SaurabhUsmani, SaadLarson, SarahNiesvizky, RubenMatous, JeffreyGasparetto, CristinaHolkova, BeataLunning, MatthewValent, JasonAnderson, Larry D., Jr.Karanes, ChatchadaKwei, LongChang, LipoGraef, ThorstenBilotti, ElizabethMcDonagh, Kevin
- [45] Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results[J]. BLOOD, 2011, 118 (21) : 290 - 291Richardson, Paul G.Siegel, David S.Vij, RaviHofmeister, Craig C.Jagannath, SundarChen, ChristineLonial, SagarJakubowiak, Andrzej J.Bahlis, Nizar J.Baz, RachidLarkins, GailChen, MinZaki, MohamedAnderson, Kenneth C.
- [46] A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy[J]. BLOOD, 2021, 138Yacoub, AbdulraheemPatnaik, Mrinal M.Ali, HarisWang, Eunice S.Gupta, VikasLee, SangminSchiller, Gary J.Taparia, Minakshi S.Pardanani, AnimeshTefferi, AyalewVerstovsek, SrdanKhoury, Joseph D.Brooks, Christopher L.Mughal, Tariq I.Pemmaraju, Naveen
- [47] Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome[J]. CANCER, 2018, 124 (13) : 2758 - 2765Assi, RitaKantarjian, Hagop M.Kadia, Tapan M.Pemmaraju, NaveenJabbour, EliasJain, NitinDaver, NavalEstrov, ZeevUehara, TaisukeOwa, TakashiCortes, Jorge E.Borthakur, Gautam
- [48] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study[J]. BLOOD, 2021, 138Budde, L. ElizabethSehn, Laurie H.Matasar, Matthew J.Schuster, Stephen J.Assouline, SaritGiri, PratyushKuruvilla, JohnCanales, MiguelDietrich, SaschaFay, KeithKu, MatthewNastoupil, LorettaWei, Michael C.Yin, ShenDoral, Michelle Y.Li, Chi-ChungHuang, HuangNegricea, RalucaPenuel, EliciaO'Hear, CarolBartlett, Nancy L.
- [49] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received.2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S387Budde, Elizabeth L.Sehn, Laurie H.Matasar, MatthewSchuster, Stephen J.Assouline, SaritGiri, PratyushKuruvilla, JohnCanales, MiguelDietrich, SaschaFay, KeithKu, MatthewNastoupil, LorettaWei, Michael C.Yin, ShenDoral, Michelle Y.Li, Chi-ChungHuang, HuangNegricea, RalucaPenuel, EliciaO'Hear, CarolBartlett, Nancy L.
- [50] Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study[J]. BLOOD, 2021, 138Terpos, EvangelosKastritis, EfstathiosHatjiharissi, EvdoxiaKatodritou, EiriniPapaiakovou, Evangelos EleutherakisVerrou, EvgeniaGavriatopoulou, MariaLeonidakis, AlexandrosNtanasis-Stathopoulos, IoannisDelimpasi, SosanaKyrtsonis, Marie-ChristinePapaioannou, MariaSymeonidis, ArgirisDimopoulos, Meletios A.